Ronald Feitosa Pinheiro

ORCID: 0000-0003-3546-0974
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Lymphoma Diagnosis and Treatment
  • DNA Repair Mechanisms
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Hemoglobinopathies and Related Disorders
  • Bone and Joint Diseases
  • Chronic Myeloid Leukemia Treatments
  • Hematological disorders and diagnostics
  • Eosinophilic Disorders and Syndromes
  • Cancer Genomics and Diagnostics
  • Mycobacterium research and diagnosis
  • Cancer therapeutics and mechanisms
  • Iron Metabolism and Disorders
  • Neutropenia and Cancer Infections
  • CNS Lymphoma Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Microtubule and mitosis dynamics
  • Viral-associated cancers and disorders
  • Ubiquitin and proteasome pathways
  • Autophagy in Disease and Therapy
  • RNA modifications and cancer
  • Chemotherapy-related skin toxicity

Universidade Federal do Ceará
2016-2025

Columbia University Irving Medical Center
2016-2023

Associação Paulista para o Desenvolvimento da Medicina
2023

Hospital Universitário Walter Cantídio
2009-2022

Universidade Federal de São Paulo
2002-2016

Faculdade de Ciências Médicas de Minas Gerais
2012

Hospital Haroldo Juaçaba
2009

Associação Paulista de Medicina
2008

Fundação de Apoio à Universidade Federal de São Paulo
2006

Hospital Santa Paula
2004

BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters cytogenetic abnormalities. Somatic gene mutations not yet used in risk of patients with MDS. METHODS: To develop a clinical-molecular prognostic model (IPSS-Molecular [IPSS-M]), pretreatment diagnostic or peridiagnostic samples from 2957 MDS were profiled 152 genes. Clinical...

10.1056/evidoa2200008 article EN NEJM Evidence 2022-06-12

10.1038/s41591-020-1008-z article EN Nature Medicine 2020-08-03

Severe diarrhoea, a common gastrointestinal manifestation of anticancer treatment with irinotecan, might involve single nucleotide polymorphisms (SNPs) toll-like receptors (TLRs), described as critical bacterial sensors in the gut. Here, colorectal cancer patients carrying missense TLR4 A896G (rs4986790) or C1,196T (rs4986791) SNPs and Tlr4 knockout (Tlr4-/-) mice were given irinotecan to investigate severity induced diarrhoea.Forty-six treated irinotecan-based regimens had diarrhoea...

10.1111/bph.15609 article EN British Journal of Pharmacology 2021-07-03

Anemia is the defining feature in most patients with myelodysplastic syndromes (MDS), yet defects erythropoiesis have not been well characterized. We examined freshly obtained bone marrow (BM) samples for stage-specific abnormalities during terminal erythroid differentiation (TED) from 221 (MDS, n = 205 113 unique patients; normal, 16) by measuring surface expression of glycophorin A, band 3, and integrin α-4. Clinical biologic associations were sought presence or absence TED specific stage...

10.1182/bloodadvances.2018018440 article EN cc-by-nc-nd Blood Advances 2018-06-14

Aims To study the immunoexpression of proteins related to mitotic checkpoint (cell division cycle 20 (CDC20), arrest deficient 2 (MAD2)) and spindle (Aurora-B) in patients with myelodysplastic syndrome (MDS). Methods Protein expression was analysed bone marrow tissue samples from 40 MDS using immunohistochemistry. Prognostic markers (transfusion dependency, depth cytopenias, chromosomal abnormalities survival) were also studied. Results Higher MAD2 observed among platelets <50×10 9 /L...

10.1136/jclinpath-2014-202728 article EN Journal of Clinical Pathology 2015-01-30

Myelodysplastic syndrome (MDS) patients with a normal karyotype constitute heterogeneous group from biological standpoint and their outcome is often unpredictable. Interphase fluorescence in situ hybridization (I-FISH) studies could increase the rate of detection abnormalities, but previous reports literature have been contradictory. We performed I-FISH conventional karyotyping (G-banding) on 50 MDS at diagnosis, after 6 12 months or any time if transformation to acute myeloid leukemia (AML)...

10.1590/s0100-879x2009001100018 article EN cc-by Brazilian Journal of Medical and Biological Research 2009-10-22

Abstract Some studies show that alterations in DNA repair genes polymorphisms are associated with the pathogenesis and susceptibility of Myelodysplastic Syndrome (MDS). We genotyped 60 MDS patients for six gene polymorphisms: BRCA1 rs4793191, BRCA2 rs9567623, RAD51 rs1801320, XRCC5 rs3835, XRCC6 rs2267437 LIG4 rs1805388. The G/C heterozygote genotype rs1801320 polymorphism was a decreased chance developing ( p = 0.05). Additionally, G/G homozygous presence one cytopenia whole blood. C/G CG +...

10.1002/hon.2175 article EN Hematological Oncology 2014-10-13

There are previously reported data describing differences between Asian and European patients with Myelodysplastic Syndromes (MDS), few direct comparisons based on cancer registration characteristics or using cohorts to validate scoring systems. This is the first study from South-America, which attempts describe demographic, clinical features, outcome of MDS patients. We retrospectively analyzed 1,080 de novo Argentina (635), Brazil (345), Chile (100). Chilean were younger (P = 0.001) female...

10.1002/ajh.24097 article EN American Journal of Hematology 2015-06-24

The increase of H. pylori resistance to clarithromycin is a concern. This study evaluated the prevalence pylori's primary and its association with virulence factors in adult dyspeptic patients asymptomatic children. gastric mucosa from (153 gastritis, 24 cancer, 21 peptic ulcer) juice obtained by string test 23S rRNA positive children were included. was assessed TaqMan RT-PCR point mutations, A2142G and/or A2143G, markers PCR. Overall, 14.4% (32/222), 14.2% adults, 12% children, whereas...

10.1590/s1678-9946202264047 article EN Revista do Instituto de Medicina Tropical de São Paulo 2022-01-01

Primary malignant breast lymphoma (PBL) is a rare disease with an incidence of 0.04-0.5% all neoplasms. The majority cases are B-cell lymphomas and the most common histologic type diffuse large (DLCL). In this study, we report our experience three PBL. treatment was same currently indicated for early stage aggressive NHL, i.e. anthracycline based chemotherapy followed by involved field radiation therapy. Unfortunately, two patients underwent mastectomy to carry out correct diagnosis. alive...

10.1080/1042819021000040369 article EN Leukemia & lymphoma/Leukemia and lymphoma 2002-11-20
Coming Soon ...